Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Adams Harkness Cuts Emisphere to 'Market Perform'

Adams Harkness downgraded Emisphere Technologies (EMIS) to market perform from strong buy.

The drug maker says initial results from a study with for a oral heparin, prevention of blood clots in hip replacement surgery patients, did not demonstrate superiority to Aventis's Lovenox. Analyst Carol Werther says that a positive result from this study was central to her thesis, adding that her model was dependent upon oral liquid heparin sales beginning in 2004. Werther says it 's now unclear whether the company will go forward with its existing formulation or discontinue the program entirely. She doesn't think a Phase III oral liquid heparin trial will be conducted, and believes shares could trade down to cash or about $6.70 on Tuesday.

blog comments powered by Disqus